-
de novo profile of m6A sites by detecting increased mismatches around modified RNA bases [16] or by focusing on specific types of sequences through fraction modification values [17].Here, we propose
-
-based gene therapy for mitochondrial disease caused by mutations in the gene encoding the mitochondrial DNA polymerase subunit gamma (POLG). The successful candidate will work under the supervision of Dr
Enter an email to receive alerts for agent-based-simulation-"Multiple" positions